Ubs Group Ag Pliant Therapeutics, Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 628,281 shares of PLRX stock, worth $848,179. This represents 0.0% of its overall portfolio holdings.
Number of Shares
628,281
Previous 230,308
172.8%
Holding current value
$848,179
Previous $2.58 Million
220.57%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
64.8MCall Options Held
228KPut Options Held
772K-
Deep Track Capital, LP Greenwich, CT5.97MShares$8.06 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$6.71 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.63MShares$6.26 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$4.36 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.2MShares$4.32 Million1.61% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $65.7M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...